Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | RGS12 | O14924 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761526 | 0.88 | EGFR (0.64) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL13936251 | 0.88 | EGFR (0.64) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL8743696 | 0.86 | EGFR (1.00) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL10615624 | 0.85 | EGFR (0.61) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL23956815 | 0.84 | CYP1A2 (0.63) | EGFRCYP1A2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22259727 | 0.84 | EGFR (0.59) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL27441151 | 0.83 | EGFR (0.58) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL12955890 | 0.82 | EGFR (0.61) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL13955019 | 0.82 | EGFR (0.66) | EGFRCYP1A2ALDH1A1KDM4EMAPT | |
| SCHEMBL11522948 | 0.82 | EGFR (0.66) | EGFRCYP1A2ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377194-B2 | JAB1 inhibitory compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220023506-A1 | JAB1 Inhibitory Compositions for Ossification and Methods Related Thereto | EMORY UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
| US-11220497-B2 | — | — | 2022-01-11 | — | — | US | disclosed |
| US-20210376381-A1 | ADDITIVES FOR ELECTROLYTES IN Li-IONS BATTERIES | HYDRO-QUéBEC (CA) | 2021-12-02 | — | — | US | disclosed |
| US-11179500-B2 | JAB1 inhibitory compositions for ossification and methods related thereto | EMORY UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210305555-A1 | ADDITIVES FOR ELECTROLYTE AND CATHODE MATERIAL IN Li-ION BATTERIES COMPRISING METAL-BASED CATHODE MATERIAL WHICH PRODUCES M2+ METAL IONS | HYDRO-QUéBEC (CA) | 2021-09-30 | — | — | US | disclosed |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-23 | — | — | US | disclosed |
| WO-2020069619-A1 | ADDITIVES FOR ELECTROLYTES IN LI-ION BATTERIES | HYDRO-QUéBEC (CA) | 2020-04-09 | — | — | WO | disclosed |
| US-20130344165-A1 | JAB1 INHIBITORY COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012116137-A2 | JAB1 BLOCKING COMPOSITIONS FOR OSSIFICATION AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2012-08-30 | — | — | WO | disclosed |
| US-7491486-B2 | Optical information recording medium | FUJIFILM CORPORATION (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491486-B2 | Optical information recording medium | FUJIFILM CORPORATION (JP) | 2009-02-17 | — | — | US | disclosed |
| EP-1004584-A2 | Pyranoquinoline derivatives as inhibitors of cell proliferation | ELI LILLY AND COMPANY LIMITED (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-5434160-A | Autoimmune diseases; prevention of excess cell proliferation or enzyme release | LILLY INDUSTRIES LIMITED (GB) | 1995-07-18 | — | — | US | disclosed |
| EP-0599514-A2 | Pyranoquinoline derivatives as inhibitors of cell proliferation | LILLY INDUSTRIES LIMITED (GB) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325901-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | EGFR 4261/4885CYP1A2 46/4885ALDH1A1 474/4885 |
| US-11220497-B2 | — | PTGES, PTGS1, PTGES2 | EGFR 4553/4885CYP1A2 39/4885ALDH1A1 551/4885 |
| US-20200231583-A1 | Prostaglandin E Synthase Inhibitors and Methods for Utilizing the Same | PTGES, PTGS1, PTGES2 | EGFR 4261/4885CYP1A2 46/4885ALDH1A1 474/4885 |
| US-20210376381-A1 | ADDITIVES FOR ELECTROLYTES IN Li-IONS BATTERIES | NDUFB9, SLC26A4, SLC9B2 | EGFR 3337/4885CYP1A2 1195/4885ALDH1A1 638/4885 |
| US-12030877-B2 | Prostaglandin E synthase inhibitors and methods for utilizing the same | PTGES, PTGS1, PTGES2 | EGFR 4261/4885CYP1A2 46/4885ALDH1A1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.